Advertisement
IQV vs MEDP
Which Stock Would AI Choose? IQVIA Holdings Inc. (IQV) vs. Medpace Holdings, Inc. (MEDP) Stock Comparison
Key Takeaways
- IQV boasts a larger market capitalization of approximately $26.5 billion compared to MEDP's $11.9 billion, reflecting greater scale in healthcare services.
- Both stocks have experienced downward pressure in recent market activity, with IQV trading around $158 and MEDP near $418 as of early May 2026.
- MEDP reported stronger recent revenue growth at 26.5% in Q1 2026, outpacing IQV's 10.3% in Q4 2025, though backlog concerns weighed on its shares.
- IQV trades at a lower trailing P/E ratio (price-to-earnings) of 20.12 versus MEDP's 26.24, suggesting relatively cheaper valuation.
- Investor sentiment for both reflects caution amid pharma R&D spending trends, with IQV facing AI competition fears and MEDP dealing with elevated cancellations.
Introduction
IQVIA Holdings Inc. (IQV) and Medpace Holdings, Inc. (MEDP) are key players in the clinical research organization (CRO) and healthcare analytics sectors, serving pharmaceutical and biotech firms amid evolving drug development demands. This stock comparison analyzes their recent performance, financial metrics, and market positioning, offering insights for traders monitoring healthcare services relative performance. Investors seeking exposure to R&D outsourcing trends or evaluating stock comparison in a volatile biotech landscape will find value in understanding contrasts in scale, growth trajectories, and sentiment shifts.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) is a global leader in healthcare intelligence, providing data analytics, technology solutions, and clinical research services to life sciences companies. In recent market activity, IQV shares have faced downward pressure, trading around $158 after declining from levels near $225 earlier in the year, influenced by concerns over AI competition and a stock issuance plan despite solid Q4 2025 results. The company reported Q4 revenue of $4.36 billion, up 10.3% year-over-year, with EPS of $3.42 beating estimates, supported by durable demand and backlog growth. Positive developments include an AI platform launch with NVIDIA and upcoming Q1 2026 earnings on May 5, bolstering sentiment amid broader pharma R&D stability.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) operates as a full-service CRO, focusing on Phase I-IV clinical development for biotech, pharma, and medtech clients. Shares have pulled back in recent weeks to around $418 from highs near $600, following a post-earnings drop despite Q1 2026 revenue of $706.6 million, up 26.5% year-over-year and beating forecasts. Performance was tempered by elevated cancellations and weaker gross bookings, raising backlog replenishment concerns and pressuring market positioning. Analyst adjustments, such as Barclays lowering its price target, reflect caution, though strong net new business awards provide some offset in this competitive CRO environment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from over 351 available, each designed to trade thousands of tickers across diverse strategies like trend following, swing trading, and multi-agent systems on timeframes from 5 minutes to 60 days. These bots display impressive stats, including annualized returns ranging from 23% to 163%, win rates up to 88%, profit factors as high as 11.7, and profit-to-drawdown ratios exceeding 2.6 in sectors like semiconductors, data centers, and industrials. Tailored for current market conditions, they offer varying risk profiles and performance histories to suit different trader styles. Explore these bots to enhance your trading with data-driven automation.
Head-to-Head Comparison
IQV and MEDP both thrive in healthcare services but differ in business models: IQV offers diversified data analytics alongside CRO services, providing broader sector exposure, while MEDP emphasizes pure-play clinical trials. Growth drivers highlight MEDP's superior recent revenue expansion at 26.5% versus IQV's 10%, yet IQV benefits from larger scale and AI catalysts. Recent momentum shows both underperforming amid R&D spending scrutiny, with MEDP facing higher risk from backlog volatility and cancellations compared to IQV's stable outlook. Valuation favors IQV on lower P/E, while market sentiment weighs trade-offs in growth versus stability.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward IQV over MEDP, citing greater trend consistency from its diversified revenue, robust backlog, and AI-driven catalysts amid recent stability. While MEDP shows higher growth potential, backlog risks introduce volatility; IQV's relative positioning and lower valuation offer a probabilistic edge in the near term for healthcare services exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and MEDP is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 5 TA indicator(s) are bullish while MEDP’s TA Score has 6 bullish TA indicator(s).
- IQV’s TA Score: 5 bullish, 4 bearish.
- MEDP’s TA Score: 6 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -1.08% price change this week, while MEDP (@Medical Specialties) price change was +2.88% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
MEDP is expected to report earnings on Jul 27, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | MEDP | IQV / MEDP | |
| Capitalization | 30.3B | 13.3B | 228% |
| EBITDA | 3.52B | 591M | 595% |
| Gain YTD | -19.498 | -16.792 | 116% |
| P/E Ratio | 22.54 | 29.41 | 77% |
| Revenue | 16.6B | 2.68B | 620% |
| Total Cash | 2.1B | 653M | 322% |
| Total Debt | 16.1B | 122M | 13,197% |
IQV | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 37 | |
SMR RATING 1..100 | 42 | 15 | |
PRICE GROWTH RATING 1..100 | 51 | 47 | |
P/E GROWTH RATING 1..100 | 49 | 30 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IQV's Valuation (62) in the Servicestothe Health Industry industry is in the same range as MEDP (78) in the Miscellaneous Commercial Services industry. This means that IQV’s stock grew similarly to MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (37) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for IQV (100) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew somewhat faster than IQV’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is in the same range as IQV (42) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
MEDP's Price Growth Rating (47) in the Miscellaneous Commercial Services industry is in the same range as IQV (51) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
MEDP's P/E Growth Rating (30) in the Miscellaneous Commercial Services industry is in the same range as IQV (49) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
| IQV | MEDP | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 80% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 66% | 3 days ago 82% |
| MACD ODDS (%) | 3 days ago 63% | 3 days ago 75% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 74% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 75% |
| Advances ODDS (%) | 6 days ago 58% | 6 days ago 74% |
| Declines ODDS (%) | 4 days ago 65% | 19 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 54% | 3 days ago 61% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 76% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.22% | ||
| CRL - IQV | 75% Closely correlated | -0.29% | ||
| TMO - IQV | 71% Closely correlated | -1.33% | ||
| MEDP - IQV | 69% Closely correlated | -1.63% | ||
| RVTY - IQV | 66% Loosely correlated | -1.83% | ||
| A - IQV | 63% Loosely correlated | +0.22% | ||
More | ||||
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with IQV. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -1.63% | ||
| IQV - MEDP | 66% Loosely correlated | +0.22% | ||
| CRL - MEDP | 52% Loosely correlated | -0.29% | ||
| TMO - MEDP | 46% Loosely correlated | -1.33% | ||
| BRKR - MEDP | 43% Loosely correlated | -1.72% | ||
| RVTY - MEDP | 39% Loosely correlated | -1.83% | ||
More | ||||